Market Overview

YM Biosciences Sells Nimotuzumab Assets by CIMYM

Related YMI
YM Biosciences Wins Final Court Order Approving Plan of Arrangement with Gilead
UPDATE: Bloom Burton Downgrades YM BioSciences to Hold Post Gilead Acquisition

YM BioSciences Inc. (NYSE: YMI) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys PTE Ltd., a company based in Singapore, for undisclosed consideration including an immediate US$2 million payment. CIMYM was a joint venture subsidiary 80% owned by YM BioSciences and 20% owned by CIMAB S.A. (representing Centro de Inmunología Molecular, Cuba). CIMAB S.A. has reported it has partnered with InnoKeys and they have incorporated a joint venture called InnoMab PTE Ltd, which is now the owner of the assets related to nimotuzumab.

Posted-In: News Asset Sales

 

Related Articles (YMI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters